IL17A and psoriasis: After systemic IL-17A blockade (12 weeks of anti-IL-17A monoclonal antibody injections), the expression of IL17A in the CD161+ T-cell cluster was decreased to zero in psoriasis lesional skin (Figures 4B, C, and Supplementary Table 3; p < 0.05).